NEW YORK (GenomeWeb News) — Insight Genetics said yesterday that it has received a new $1.5 million grant from the National Cancer Institute.

The Phase II Small Business Innovation Research grant from the National Cancer Institute will enable Nashville, Tenn.-based Insight to continue developing Insight ALK Resistance, a molecular diagnostic test to help clinicians monitor therapeutic resistance in non-small cell lung cancer patients.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genomic analysis of Malaysian tuberculosis strain, database of bat genomes, and more.

An editorial appearing at The Scientist bemoans the high numbers of mitochondrial genome papers and suggests a different path for mitochondrial genome research.

Researchers and drug developers are excited about the potential of CRISPR-Cas9-based therapeutics, the Wall Street Journal reports.

US lawmakers want to develop a new incarnation of the National Children's Study, ScienceInsider reports.